Ajinomoto becomes first partner for Albireo's lead drug elobixibat

Albireo has struck the first alliance for its lead development project, the bowel disorder drug elobixibat (A3309), with Ajinomoto Pharmaceuticals for a number of Asian markets including Japan.

Albireo has struck the first alliance for its lead development project, the bowel disorder drug elobixibat (A3309), with Ajinomoto Pharmaceuticals for a number of Asian markets including Japan.

In a separate development, the Japanese firm - part of the diversified Ajinomoto seasonings, foods and drinks group - also...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category